Stocktoria
BridgeBio Oncology Therapeutics, Inc. BBOT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-02-09
Chart by TradingView
3/9
Piotroski F — financial health
12.61
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$145.8M | -$80.9M | -$41,692 |
| Net income | -$134.0M | -$74.3M | -$41,692 |
| Operating cash flow | -$113.9M | -$55.0M | — |
| Free cash flow | -$114.5M | -$55.1M | — |
| Total assets | $448.4M | $164.3M | $332,894 |
| Total liabilities | $37.3M | $19.6M | $396,463 |
| Shareholders' equity | $411.1M | -$178.6M | -$115.6M |
| Ratios | |||
| Return on assets | -29.9% | -45.2% | -12.5% |
| Return on equity | -32.6% | 41.6% | 0.0% |
| Current ratio | 12.34 | 8.10 | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 101,900 | $912,005 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 12.61 (safe)
- Working capital / assets 0.886
- Retained earnings / assets -0.795
- EBIT / assets -0.325
- Equity / liabilities 11.026
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001869105 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.